mdfxpress.blogg.se

Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count Losartan Potassium /Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 90 count Losartan Potassium/ Hydrochlorothiazide Tablets, USP 50mg/12.5mg, 30 count Losartan Potassium Tablets, USP 100mg, 1000 count Losartan Potassium Tablets, USP 100mg, 90 count

Losartan Potassium Tablets, USP 50mg, 1000 count Losartan Potassium Tablets, USP 50mg, 90 count Losartan Potassium Tablets, USP 50mg, 30 count Losartan Potassium Tablets, USP 25mg, 1000 count Losartan Potassium Tablets, USP 25mg, 90 count Losartan Potassium Tablet and Losartan Potassium/ Hydrochlorothiazide Tablet Lotsįinished Product Strength and Package Count The product can be identified by checking the product name, manufacturer details and batch or lot number on the bottle containing these products. The product/lots included in the expanded recall are listed below in red.

Patients should contact their pharmacist or physician who can advise them about an alternative treatment prior to returning their medication. Patients who are taking Losartan Potassium Tablets, USP and Losartan Potassium/Hydrochlorothiazide Tablets, USP should continue taking their medication, as the risk of harm to the patient’s health may be higher if the treatment is stopped immediately without any alternative treatment.

Losartan potassium and hydrochlorothiazide tablets, USP is used to treat hypertension and hypertensive patients with Left Ventricular Hypertrophy. Losartan is used to treat hypertension, hypertensive patients with Left Ventricular Hypertrophy and for the treatment of nephropathy in Type 2 diabetic patients. To date, Torrent Pharmaceuticals Limited has not received any reports of adverse events related to this recall.

Torrent is only recalling lots of losartan-containing products that contain N-Methylnitrosobutyric acid (NMBA) above the acceptable daily intake levels released by the FDA. The impurity detected in the API is N-Methylnitrosobutyric acid (NMBA). The Recall is expanded to include an additional 36 lots of Losartan potassium Tablets USP and 68 lots of Losartan Potassium/Hydrochlorothiazide Tablets, USP Torrent Pharmaceuticals Limited is expanding its recall for Losartan Potassium Tablets USP and Losartan Potassium/hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. Losartan potassium tablets, USP Losartan potassium and Hydrochlorothiazide tablets, USP